Effect of Achieving Sustained Virological Response Before Hepatitis C Virus-related Hepatocellular Carcinoma Occurrence on Survival and Recurrence After Curative Surgical Microwave Ablation
Overview
Authors
Affiliations
Background And Aim: The effects of achieving sustained virological response (SVR) on recurrence and survival after curative treatment in patients with hepatitis virus C (HCV)-related hepatocellular carcinoma (HCC) is unclear. This study examined the influence of SVR achievement by interferon therapy before HCC occurrence on recurrence and survival.
Methods: This retrospective study included 518 patients who underwent surgical microwave ablation for initial HCV-related HCC between January 2001 and December 2015. Thirty-four patients had achieved SVR (SVR group) and 484 patients had not (control group). Clinical characteristics and long-term outcomes were compared between the two groups.
Results: Overall survival rates at 5 and 10 years after curative ablation were 95.8 and 80.4% in the SVR group, and 50.7 and 23.4% in the control, respectively (p < 0.0001). Recurrence-free survival rates at 5 and 10 years were 68.7 and 26.4% in the SVR group, and 24.5 and 7.8% in the control group, respectively (p < 0.0001). Multivariate analyses revealed that achieving SVR as an independent prognostic factor for both overall and recurrence-free survival. In the SVR group, the 5-year recurrence-free survival rates for patients with an interval of 5 years or fewer (n = 24) vs. more than 5 years (n = 10) between achieving SVR and curative ablation were 58.7 and 88.9%, respectively (p = 0.03).
Conclusions: Achieving SVR before HCC occurrence allowed a favorable clinical outcome after curative ablation in HCV-related HCC patients. Patients with HCC that occurred more than 5 years after achieving SVR had longer recurrence-free survival.
Itani M, Farah B, Wasvary M, Wadehra A, Wilson T, Rutledge B J Gastrointest Cancer. 2024; 55(3):1324-1332.
PMID: 38972941 DOI: 10.1007/s12029-024-01076-w.
Consensus on the tertiary prevention of primary liver cancer.
Nan Y, Xu X, Dong S, Yang M, Li L, Zhao S Hepatol Int. 2023; 17(5):1057-1071.
PMID: 37369911 PMC: 10522749. DOI: 10.1007/s12072-023-10549-2.
Hsu P, Liang P, Huang C, Hsieh M, Tsai Y, Lin T Viruses. 2022; 14(11).
PMID: 36366510 PMC: 9693099. DOI: 10.3390/v14112412.
Sun Y, Zhang H, Long J, Zhang Y, Zheng J, Yuan C Front Oncol. 2022; 12:978614.
PMID: 36212462 PMC: 9539218. DOI: 10.3389/fonc.2022.978614.
An C, Li X, Yu X, Cheng Z, Han Z, Liu F Cancer Biol Med. 2020; 16(4):797-810.
PMID: 31908896 PMC: 6936230. DOI: 10.20892/j.issn.2095-3941.2018.0486.